Light Sciences to Present at Windhover Information's ``The Start-Up Forum 2005''.BOSTON -- Light Sciences has announced that it will be presenting at 2:10 p.m. Thursday May 19 at Windhover Information's "The Start-Up Forum 2005," taking place May 18-20, 2005 at the Cambridge Marriott in Boston, MA. Albert Luderer, Ph.D., President and CEO (1) (Chief Executive Officer) The highest individual in command of an organization. Typically the president of the company, the CEO reports to the Chairman of the Board. , will provide an overview of the company, its subsidiaries and Light Infusion Technology(TM) (Litx(TM)). About Light Sciences Light Sciences Corporation, founded in 1995, is a privately financed company developing Light Infusion Technology (Litx), a proprietary combination product containing a photoreactive agent (LS11) activated by non-coherent light infusion devices. In 2005, Light Sciences Corporation created three unique, subsidiary companies developing Litx for eye disease, cancer and cardiovascular disease Cardiovascular disease Disease that affects the heart and blood vessels. Mentioned in: Lipoproteins Test cardiovascular disease respectively: --Visient Therapeutics, Inc.: Targeting age-related macular degeneration Age-related macular degeneration (ARMD) Degeneration of the macula (the central part of the retina where the rods and cones are most dense) that leads to loss of central vision in people over 60. (AMD (Advanced Micro Devices, Inc., Sunnyvale, CA, www.amd.com) A major manufacturer of semiconductor devices including x86-compatible CPUs, embedded processors, flash memories, programmable logic devices and networking chips. ) and other eye diseases, Visient Therapeutics is recruiting patients for a Phase 1/2 clinical trial in patients with the wet form of AMD. Age-related macular degeneration is the leading cause of blindness in the population aged more than 50 years. --Light Sciences Oncology, Inc.: Targeting primary liver cancer, colorectal liver metastases Metastasis (plural, metastases) A tumor growth or deposit that has spread via lymph or blood to an area of the body remote from the primary tumor. Mentioned in: Malignant Melanoma and other solid tumors, Light Sciences Oncology has finished a global multi-center Phase 2 clinical trial phase 2 clinical trial Phase 2 study. See Phase study. treating patients with liver metastases due to colorectal cancer. Metastatic Metastatic The term used to describe a secondary cancer, or one that has spread from one area of the body to another. Mentioned in: Coagulation Disorders metastatic pertaining to or of the nature of a metastasis. colorectal cancer is a leading cause of cancer death in the western world, with nearly 60,000 fatalities annually in the U.S. alone. The company plans to begin a Phase 2 trial of Litx in May 2005 in patients with hepatocellular carcinoma, which is among the most malignant of cancers and afflicts more than 1,000,000 people per year worldwide. --Vascular Reconditioning, Inc.: Targeting atherosclerosis, Vascular Reconditioning is developing a new treatment for interventional cardiologists to use against vulnerable plaque, the underlying disease trigger in over one million coronary attacks in Americans each year, from which around 40% will die. Light Sciences(R), Litx(TM), Light Infusion Technology(TM) are registered or proprietary marks of Light Sciences Corporation. |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion